Home
Test for alterations
The VISION trial
Efficacy
Safety, QoL and Dosing

Timely targeted therapy is essential for patients with METex14 skipping NSCLC1

METex14 skipping NSCLC prognosis
Flexible biopsy options

METex14 skipping NSCLC prognosis

Patients with METex14 skipping NSCLC face a significantly worse prognosis than those without the alteration2

3-4%

3-4% of your patients with NSCLC may have METex14 skipping – with up to 6% of NSCLC affected by oncogenic MET alterations2–4

LESS THAN

30%

Less than 30% of treatment-naïve patients with METex14 skipping NSCLC respond to non-targeted treatments5

Adapted from Tong et al. 20162

Test early for METex14 skipping to identify your patients who could benefit from TEPMETKO6,7

Flexible biopsy options

Advantages and limitations of tissue and liquid biopsies8,9

Where tissue biopsy is not possible or suitable due to factors such as comorbidities or frailty, liquid biopsy is a viable alternative8

TISSUE BIOPSY

Tissue bipsymet-pathway

Advantages

  • Current gold standard for identifying TEPMETKO-eligible patients
  • Highly accurate

Limitations

  • Invasive
  • Risk of complications
  • Lack of or inaccessible tissue
  • Re-biopsies may be more difficult due to diminishing tissue or increased risk

LIQUID BIOPSY

abcsmet-pathway

Advantages

  • Non-invasive
  • Faster turnaround
  • Enables ongoing monitoring

Limitations

  • Not yet widely available
  • Lack of standardization of testing
  • Less sensitive

Test early for METex14 skipping to identify your patients who could benefit from TEPMETKO6,7

With TEPMETKO, give your patients more moments that matter

Explore the VISION trial

Learn more about the patient characteristics, efficacy outcomes and design of VISION, a single-arm, open-label, multicenter, non-randomized, multi-cohort study that analyzed patients with METex14 skipping NSCLC (N=313)3,10

Learn more about the VISION trial

TEPMETKO may offer substantially increased mDOR vs. capmatinib11

A matching-adjusted indirect comparison (MAIC) of TEPMETKO vs. capmatinib has shown improved mDOR, mOS and mPFS11

Learn more about MAIC outcomes

TEPMETKO demonstrated a manageable safety profile that maintained QoL10,12–15

Most common AEs were mild to moderate13

Learn more about safety, dosing and QoL
Abbreviations

AE, adverse event; MAIC, matching-adjusted indirect comparison; mDOR, median duration of response; METex14, mesenchymal epithelial transition factor exon 14; mOS, median overall survival; mPFS, median progression-free survival; NSCLC, non-small cell lung cancer; OS, overall survival; QoL, quality of life

References
  1. Awad MM et al. Lung Cancer  2019; 133:96–102.
  2. Tong JH et al. Clin Cancer Res  2016; 22:3048–3056.
  3. Paik PK et al. N Engl J Med  2020; 383:931–943.
  4. Salgia R. Mol Cancer Ther  2017; 16:555–565.
  5. Viteri S et al. Presented at: European Society for Medical Oncology (ESMO) 2023; 20–24 October 2023; Madrid, Spain (Poster no. 1380P).
  6. Socinski MA et al. JCO Precis Oncol  2021; 5:653–663.
  7. Le X et al. Clin Cancer Res  2022; 28:1117–1126.
  8. Di Capua D et al. Cancers  2021; 13:3923.
  9. Rolfo C et al. Presented at: European Society for Medical Oncology (ESMO)  2023; 20–24 October 2023; Madrid, Spain (Poster no. 1382P).
  10. Mazieres J et al. JAMA Oncol  2023; 9:1260–1266.
  11. Pfeiffer BM et al. Presented at: IASLC World Conference on Lung Cancer (WCLC)  2023; 9−12 September 2023; Virtually and Singapore (Poster no. 1312).
  12. Mazieres J et al. JAMA Oncol  2023; 9:1260–1266 (supplementary appendix 2).
  13. Paik PK et al. Presented virtually at: American Society of Clinical Oncology (ASCO) Annual Meeting 2023; 2–6 June 2023; Chicago, IL, USA (Abstract no. 9060).
  14. Veillon R et al. Clin Lung Cancer  2022; 23:320–332.
  15. Ahn L et al. Clin J Oncol Nurs  2022; 26:543–551.

This website is an international information resource intended only for healthcare professionals from outside the European Economic Area (EEA), the US, Puerto Rico and Canada who are interested in information on TEPMETKO. The information on this website contains educational and promotional material. By clicking on 'I'm a healthcare professional' you are declaring and confirming that are you a healthcare professional and have read and understood this.

I’m a healthcare professional

I’m not a healthcare professional

GL-TEP-00506 | April 2025

© 2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved. TEPMETKO is a registered trademark of Merck KGaA, Darmstadt, Germany.

This website is an international information resource intended only for Healthcare Professionals from outside the European Economic Area (EEA), the US, Puerto Rico
and Canada who are interested in information on TEPMETKO.

Terms and Conditions     Privacy Policy    Legal Statement   Site Map    Contact Us

Terms and Conditions    Privacy Policy     Legal Statement    Site Map    Contact Us

Cookie Disclamer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our cookie policy.

GOT IT!
COOKIE SETTINGS

These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.

 

These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.

In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.